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Several circulating neurohormones have been shown to 
have prognostic significance in patients with chronic heart 
failure, but the relation between plasma levels of atria1 
natriuretic peptide and mortality in this disorder remains 
unknown. Plasma levels of immunoreactive atria1 natri- 
uretic peptide were measured in 102 patients in whom left 
ventricular ejection fraction, ventricular arrhythmias on 
ambulatory electrocardiographic recording and plasma lev- 
els of norepinephrine, renin activity, aldosterone and argi- 
nine vasopressin were also measured. Compared with pa- 
tients with atrial natriuretic peptide concentrations below 
the median value of 125 pg/ml, patients with higher levels of 
the peptide had a higher plasma renin activity (8.9 -C 1.8 
versus 2.6 f 0.4 ng/ml per h) and plasma norepinephrine 
(858 + 116 versus 538 & 45 pglml), more frequent prema- 
ture ventricular depolarizations (4,485 f 715 versus 2,004 
f 495/day) and more advanced hemodynamic abnormali- 
ties (all p < 0.05). 
During the subsequent 13 to 25 months of follow-up, 
patients with high levels of atria1 natriuretic peptide had a 
significantly lower rate of survival than did those whose 
initial circulating peptide concentrations were normal or 
mildly increased (p = 0.01). These data indicate that, in 
patients with chronic heart failure, plasma atrial natri- 
uretic peptide provides important prognostic information. 
This may relate to the ability of the hormone to reflect the 
interplay of several pathophysiologic factors that contribute 
to mortality in this disease. 
(.I Am Co11 Cardiol1989;13:1534-9) 
As cardiac performance declines in patients with chronic 
heart failure, various neurohormonal systems are stimulated 
in an attempt to maintain circulatory homeostasis. This 
neurohormonal activation becomes progressively more 
marked as the disease state advances (1,2) and may acceler- 
ate the deterioration of left ventricular function that occurs 
over time (3,4). Either because they are a marker of disease 
severity or play a direct pathogenetic role, circulating levels 
of many neurohormones strongly predict the long-term prog- 
nosis of patients with heart failure (4). Patients with the most 
marked activation of the sympathetic nervous system (as 
reflected by elevated plasma norepinephrine levels) and of 
From the Division of Cardiology, Department of Medicine, Mount Sinai 
School of Medicine of the City University of New York, New York, New 
York. This study was supported by grants T32 HL 07347 and ROl-HL-25055 
from the National Heart, Lung, and Blood Institute, National Institutes of 
Health, Bethesda, Maryland. Dr. Packer is the recipient of a Research Career 
Development Award (KO4-HL 01229) from the National Institutes of Health. 
Manuscript received August 8.1988; revised manuscript received Novem- 
ber 22, 1988, accepted January 9, 1989. 
*Current address and address for reorints: Stephen S. Gottlieb, MD, 
Division of Cardiology, University of Maryland School of Medicine, 22 South 
Greene Street, Baltimore, Maryland 21201. 
01989 by the American College of Cardiology 
the renin-angiotensin system (as reflected by hyponatremia) 
have the highest mortality rate (5,6). These neurohormonal 
measurements may provide more powerful prognostic infor- 
mation than do the invasive and noninvasive variables that 
are conventionally used to assess left ventricular function 
(536). 
Previous studies that have evaluated the relation between 
neurohormones and survival in chronic heart failure have 
focused on the activation of vasoconstrictor systems. Pa- 
tients with advanced left ventricular dysfunction, however, 
also have elevated levels of endogenous vasodilators (for 
example, prostaglandins and atria1 natriuretic peptide) (7- 
10); yet, it is not known whether these dilator hormones 
have prognostic significance. If, like the vasoconstrictor 
hormones, circulating levels of these vasodilators increase in 
parallel to the severity of the underlying disease, the release 
of prostaglandins and atria1 natriuretic peptide might be 
expected to be greatest in patients with the highest mortality. 
On the other hand, if the vasodilator hormones act to limit 
the deleterious effects of the vasoconstrictor systems, high 
circulating levels of endogenous vasodilators might be asso- 
ciated with a favorable long-term outcome. To distinguish 
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between these two possibilities, we evaluated the relation 
between plasma atria1 natriuretic peptide and long-term 
survival in 102 patients with chronic heart failure. 
Methods 
Study patients. Our study group consisted of 102 patients 
with chronic congestive heart failure recruited over a 12 
month period. There were 81 men and 21 women, aged 34 to 
90 years (mean 64). The cause of heart failure was dilated 
cardiomyopathy in 53 patients, ischemic heart disease in 43 
patients and primary mitral or aortic regurgitation, or both, 
in 6 patients. All patients had a left ventricular ejection 
fraction ~40% by radionuclide ventriculography. Thirty-two 
patients were in New York Heart Association functional 
class II, 39 in class III and 31 in class IV. All patients were 
clinically stable on constant doses of digoxin and diuretics; 
any previous therapy with vasodilator drugs was withdrawn 
for 220 half-lives 
Study Design 
Patients underwent the following evaluations over 2 to 5 
days: 1) hormonal measurements (all 102 patients); 2) 24 h 
ambulatory electrocardiographic (ECG) monitoring (98 pa- 
tients); and 3) right heart catheterization (34 patients). 
Hormonal analysis. After the patient had been recumbent 
in a quiet room for ~30 min, blood was collected from an 
indwelling catheter for the following analyses: I) plasma 
renin activity, aldosterone and arginine vasopressin (by 
radioimmunoassay): 2) plasma norepinephrine, epinephrine 
and dopamine (by radioenzymatic assay); and 3) plasma 
atria1 natriuretic peptide (by radioimmunoassay). For the 
last assay, blood was collected in prechilled ethylenediamine- 
tetraacetic acid (EDTA) tubes with aprotinin, and the plasma 
was separated immediately and stored at -70” C until 
extracted and analyzed as previously described (11). Blood 
was obtained in duplicate (on 2 sequential days) for all 
assays in 88 of the 102 patients. There was a strong corre- 
lation between hormonal determinations performed on the 2 
days: for example, atria1 natriuretic peptide on day 1 was 
closely correlated with atrial natriuretic peptide on day 2 (r 
= 0.91). 
Ambulatory electrocardiographic recordings. Twenty- 
four hour recordings were obtained in all patients within 24 
h of hormonal determinations; 48 h recordings were obtained 
in 88 patients. These recordings were used to measure the 
frequency of premature ventricular depolarizations and epi- 
sodes of ventricular tachycardia (23 premature ventricular 
depolarizations in a row at a rate >lOO/min). 
Hemodynamic measurements. Right heart catheterization 
and arterial cannulation were performed to measure right 
heart and systemic pressures, respectively. Patients were 
permitted to rest overnight to allow dissipation of the hemo- 
dynamic effects related to intravascular instrumentation. On 
the next morning, after all cardioactive medications were 
withheld for 212 h, the following hemodynamic variables 
were measured repeatedly with the patient in the fasting 
state until hemodynamic stability was evident: mean arterial 
pressure, heart rate, left ventricular filling pressure, mean 
right atria1 pressure and cardiac output. The methods we 
used have been described in detail previously (12). 
Mean systemic pressures were determined by electronic 
filtration. Derived hemodynamic variables were calculated 
as follow: cardiac index (CI) = CO/body surface area (liters/ 
min per m’): stroke volume index (SVI) = CUHR (ml/m’); 
stroke work index (SWI) = SVI x (MAP - LVFP) x 0.0136 
(g - m/m’); systemic vascular resistance = 80 X (MAP - 
MRAP)/CO (dynes*s.cm-‘). where CO = cardiac output, 
MRAP = mean right atrial pressure, LVFP = left ventricular 
filling pressure, HR = heart rate and MAP = mean arterial 
pressure. 
Follow-up. Survival was assessed to the day of death or 
to June 1, 1988; follow-up ranged from 13 to 25 months. 
Cumulative survival curves were constructed by Kaplan- 
Meier survivorship methods (13), and the differences be- 
tween survival curves were tested for significance by both 
Mantel-Cox log-rank and Wilcoxon-Breslow methods 
(14.15). 
Statistics. Qualitative and quantitative differences be- 
tween subgroups of patientswere tested for significance with 
use of the chi-square statistic and the t test for paired data, 
respectively. Whenever hormonal and ECG data were ob- 
tained in duplicate, the mean value was used for all calcula- 
tions. All statistical calculations were performed with Sta- 
tistical Analysis System (SAS) computer programs. Group 
data are expressed as mean values t SEM. 
Results 
Atria1 natriuretic peptide and survival. Plasma concentra- 
tions of atria1 nutriuretic peptide ranged from 11 to 650 pg/ml 
(median 125) in the 102 patients with chronic heart failure 
evaluated in this study. Eighty-nine patients had a concen- 
tration of the peptide >50 pg/ml (upper limit of normal for 
the laboratory assay). Patients with a plasma level greater 
than the median value of 125 pgiml had a significantly higher 
mortality rate than did those with a lower circulating level (p 
= 0.01 by both Wilcoxon and Mantel-Cox) (Fig. 1). 
Atria1 natriuretic peptide concentration and severity of 
heart failure. Patients with a plasma level >125 pgiml had 
clinical, neurohormonal and hemodynamic evidence for 
more severe heart failure than did patients with lower levels 
of the peptide. Patients with the higher concentrations had 
greater limitation of functional capacity, higher levels of 
plasma renin activity, aldosterone and norepinephrine and 
more severe hemodynamic abnormalities than did patients 
with lower levels (all p < 0.05) (Tables 1 and 2). Patients with 
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Figure 1. Kaplan-Meier analysis of cumulative rates of survival in 
patients with heart failure stratified into two groups on the basis of 
median plasma concentration of atria1 natriuretic peptide (ANP) (125 
pg/mU. 
higher peptide levels also tended to have a lower left Prognostic importance of peptide levels. To determine 
ventricular ejection fraction (p = 0.07) and more frequent whether the levels of atria1 natriuretic peptide seen in our 
ventricular premature depolarizations (p < 0.05) and epi- patients with heart failure had independent prognostic sig- 
sodes of ventricular tachycardia, although the last difference nificance or only reflected the importance of other factors, 
was not statistically significant because of the large variance all of the variables that differed between the high and low 
seen in patients with high peptide levels. When patients were peptide subgroups (including ejection fraction) were entered 
grouped according to circulating levels of vasoconstrictor into a Cox regression model. Because only 33% of the 
hormones, plasma levels of atria1 natriuretic peptide were patients had hemodynamic measurements, these were not 
most markedly elevated in patients with the highest levels of entered into the analysis. According to the regression model, 
plasma renin activity and norepinephrine (Fig. 2). plasma atria1 natriuretic peptide provided independent prog- 
Table 2. Hemodynamic Characteristics of 34 Patients Grouped 
According to the Median Value for Atria1 Natriuretic Pentide* 
ANP >125 
pgiml 
(n = 15) 
ANP <125 
pg/ml 
’ (n = 19) Value 
Cardiac index (litersimin m*) per 2.2 ” 0.1 1.7 ? 0.1 co.05 
Stroke work index (g-m/m*) 28 If: 4 17 c 2 co.05 
Mean arterial pressure (mm Hg) 94 + 6 82 t 3 co.05 
Left ventricular filling pressure 18 ‘- 3 26 + 2 co.05 
(mm Hg) 
Mean right atrial pressure (mm Hg) 6.5 2 1.3 9.4 2 2.0 NS 
Heart rate (beats/min) 87 2 3 79 + 3 NS 
Systemic vascular resistance 1,857 2 140 2,198 ? 141 NS 
(dynesscm-‘) 
*These patients were grouped according to the median value for atrial 
natriuretic peptide (ANP) for all 102 patients studied. NS = not significant. 
Table 1. Demographic and Neurohormonal Characteristics of 102 Patients Grouped According to 
the Median Value for Plasma Atrial Natriuretic Peptide (ANP) 
ANP >I25 pglml ANP <125 pglml P 
(n = 51) (n = 51) Value 
Age (yr) 63 + 2 64+2 NS 
Gender NS 
Male 40 41 
Female 11 10 
Cause of heart failure co.05 
ICM 26 17 
PDC 25 28 
PVD 0 6 
NYHA functional class co.05 
II 22 10 
III 19 20 
IV 10 21 
LV ejection fraction 0.21 f 0.01 0.18 t 0.01 NS 
Plasma renin activity (&ml per h) 2.6 ? 0.4 8.9 + 1.8 co.05 
Plasma aldosterone (ng/dl) 23 ? 3 43 + 7 <0.05 
Plasma norepinephrine (pg/ml) 538 ? 45 858 + 116 co.05 
Plasma epinephrine (pglml) 109 2 29 124 2 16 NS 
Plasma dopamine (pglml) 132 ? 21 169 ? 42 NS 
Plasma arginine vasopressin (pglml) 6.2 ? 0.8 8.2 2 0.9 NS 
Premature ventricular depolarizations (day-‘) 2,004 2 495 4,485 ? 715 co.05 
Ventricular tachycardia (events/day) 1.5 ‘- 0.5 106.6 ? 67 NS 
KM = ischemic cardiomyopathy; LV = left ventricular; NS = not significant; NYHA = New York Heart 
Association; PDC = primary dilated cardiomyopathy; PVD = primary valvular disease. 
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Figure 2. Plasma concentrations of atria1 natriuretic peptide (ANP) 
in patients with chronic congestive heart failure grouped according 
to the level of plasma renin activity and plasma norepinephrine. 
Patients with the highest levels of both neurohormones had signifi- 
cantly higher concentrations of atrial natriuretic peptide than did 
patients with normal levels of plasma norepinephrine and plasma 
renin activity. 
nostic information (p = 0.004) as did the functional class 
(p = 0.003) and the frequency of premature ventricular 
depolarizations (p = 0.02). Once these variables were en- 
tered into the model, other hormonal variables failed to 
contribute to the prediction of survival. 
Discussion 
Prognostic significance of atria1 natriuretic peptide. Our 
findings are the first to demonstrate that the measurement of 
atria1 natriuretic peptide is an important prognostic factor in 
patients with chronic heart failure. Patients with very high 
circulating levels of the peptide had a substantially greater 
mortality than did those with normal or only moderately 
increased levels of the hormone. Plasma concentrations of 
atria1 natriuretic peptide provided prognostic information at 
least as powerful as that provided by the measurement of 
vasoconstrictor neurohormones. 
Two factors may explain the close relation between 
survival and levels qf atria1 natriuretic peptide in our study. 
Previous studies (5,6) that have observed a relation between 
vasoconstrictor hormones and mortality have suggested that 
neurohormonal activation may contribute directly to the 
progressive deterioration of left ventricular function that 
occurs in patients with chronic heart failure. Atria1 natri- 
uretic peptide is not known to exert deleterious actions in 
these patients; however, its vasodilator and natriuretic prop- 
erties might be expected to lower ventricular wall stress (16 
18) and its ability to diminish the release of norepinephrine 
(19,20) and renin (17,21) might reduce the arrhythmogenic 
potential of these hormonal systems. All of these effects 
should have a beneficial effect on survival. Consequently, it 
is likely that the prognostic importance of atria1 natriuretic 
peptide in chronic heart failure is related to its ability to 
accurately gauge the severity of chronic heart failure and to 
reflect the interplay of the multiple factors that contribute to 
mortality in this disease. 
Relation of atria1 natriuretic peptide to symptoms. Pa- 
tients with very high levels of the peptide and the most 
unfavorable prognosis also had the most limited functional 
capacity. This observation is consistent with previous re- 
ports that circulating levels of the atrial peptide rise in 
parallel with the severity of symptoms (22.23) and that the 
functional status of patients with heart failure is an excellent 
predictor of mortality (24). The survival rate of our patients 
with very high peptide concentrations was similar to that 
previously reported in patients with class III and 1V heart 
failure (24,25). whereas patients with lower levels of the 
peptide had a mortality rate comparable with that of patients 
with only mild to moderate symptoms (26). 
Relation of atria1 natriuretic peptide to cardiac perfor- 
mance. The patients in our study with very high levels of 
atrial natriuretic peptide also demonstrated the most abnor- 
mal cardiac performance; these patients had a lower cardiac 
index and higher ventricular filling pressures than did pa- 
tients with normal or mildly elevated levels of the peptide. 
Similar findings have been reported by other investigators 
(8,271. Because patients with severe left ventricular dysfunc- 
tion have an extremely high mortality rate (38), the unfavor- 
able outcome of patients with markedly increased concen- 
trations of atria1 natriuretic peptide in our study may be 
related to the association of high levels of the hormone with 
advanced hemodynamic abnormalities. 
We could not confirm the very close relation between 
plasma atrial natriuretic peptide and mean right atria1 pres- 
sure (8,27) and left ventricular ejection fraction (29) ob- 
served in other investigations. In these previous studies, 
however. values for right atria1 pressure and ejection frac- 
tion varied widely because patients without heart failure 
were included in the analysis. In contrast, in our study, we 
evaluated only patients with heart failure. Consequently, 
there was only a narrow range of values for these two 
variables, and this may have limited our ability to discern a 
relation between plasma levels of atria1 natriuretic peptide 
and either right atrial pressure or ejection fraction. 
Relation of atria1 natriuretic peptide to vasoconstrictor 
neurohormones. Patients with the highest concentrations of 
atria1 natriuretic peptide in our study also had the highest 
circulating levels of norepinephrine and renin activity. Such 
parallel activation of both vasodilator and vasoconstrictor 
systems has not been previously reported. At first glance, 
this observation may appear to be difficult to explain because 
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a high level of atria1 natriuretic peptide might be expected to 
suppress the release of renin from the kidney and the release 
of norepinephrine from nerve terminals (19-21). Conse- 
quently, there is an inverse relation between the plasma level 
of atria1 peptide and plasma renin activity in normal individ- 
uals (7); this inverse relation is preserved during the early 
stages of congestive heart failure (30). In contrast, in our 
patients with long-standing heart failure, levels of atria1 
natriuretic peptide and renin activity were increased in 
parallel. This direct relation may in part be related to 
abnormalities of atria1 baroreflex function that are known to 
occur in chronic heart failure. In normal subjects, atria1 
stretch enhances the release of atria1 natriuretic peptide and 
suppresses adrenergic activity and the release of renin (31). 
In contrast, in chronic heart failure, despite a similar stimu- 
latory effect on peptide release, atria1 stretch fails to sup- 
press the sympathetic nervous or renin-angiotensin systems 
(32). Patients with high atria1 pressures may also have 
coexistent hemodynamic abnormalities that directly trigger 
the activation of vasoconstrictor systems. Because both 
plasma norepinephrine and renin activity are powerful prog- 
nostic factors in chronic heart failure (5,6,33), parallel 
changes in the level of atria1 natriuretic peptide in these 
patients should also predict long-term survival. 
Relation of atria1 natriuretic peptide to ventricular arrhyth- 
mias. Our patients with very high levels of atria1 natriuretic 
peptide had more frequent and complex ventricular arrhyth- 
mias than did patients with normal or mildly elevated peptide 
concentrations. This association may be related to the mag- 
nitude of ventricular dilatation because patients with the 
highest ventricular filling pressures and volumes have both 
high levels of atria1 peptide and abnormal electrophysiologic 
responses (34). In addition, because vasoconstrictor and 
vasodilator hormones were increased in parallel in our 
study, patients with elevated levels of atria1 peptides also 
had increased levels of potentially arrhythmogenic neuro- 
hormones (for example, norepinephrine and angiotensin) 
(35,36). Both ventricular arrhythmias and vasoconstrictor 
neurohormones are powerful predictors of survival in 
chronic heart failure, although both factors are thought to 
predict total mortality rather than the occurrence of sudden 
death (5,37). The lack of an association of these variables 
with sudden death must be viewed cautiously, however, 
because it is difficult to determine with confidence the mode 
of death of patients with chronic heart failure (38). Because 
of such difficulties, we made no effort to classify the mode of 
death in our study. Nevertheless, our observations suggest 
that ventricular arrhythmias may contribute to the high 
mortality rate of patients with heart failure who have high 
levels of atria1 natriuretic peptide. 
Conclusions. The measurement of atria1 natriuretic pepe- 
tide is a powerful prognostic factor in patients with chronic 
heart failure, probably because it reflects the severity of 
established risk factors for death in patients with advanced 
left ventricular dysfunction. Further work is needed to 
determine whether peptide measurements can be used in the 
clinical setting to select patients for therapeutic interven- 
tions designed to prolong life. 
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